申请人:Schreiber Stuart L.
公开号:US20120094939A1
公开(公告)日:2012-04-19
The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a compound of formulae (I) and (II), a pharmaceutically acceptable form thereof, or a pharmaceutical composition thereof. The present invention is also directed to high-throughput methods of identifying compounds able to modulate hepatitis C virus (HCV) replication activity.
本发明涉及公式(I)和(II)的化合物及其药学上可接受的形式;其药物组合物;以及通过向诊断或易感染病毒感染的受试者投与公式(I)和(II)的化合物,其药学上可接受的形式或其药物组合物来治疗病毒感染,例如丙型肝炎病毒(HCV)感染。本发明还涉及高通量方法,用于鉴定能够调节丙型肝炎病毒(HCV)复制活性的化合物。